Abstract
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the anti-infective sector. The
report includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
The anti-infectives market is the fifth largest therapeutic category. We
estimate that anti-infectives grossed sales of US$28.5 billion in 2005, with a
further US$16 billion being derived from hospital-based use and OTC. The
majority of prescription-based sales were derived from the US (around 50%)
compared to 22% in Europe and Japan. However, growth in Europe at over 5%
exceeded that of the US and Japan compared with around 3%.
View Cart
